Specifically, miR‐206 targets and reduces KLF4 expression, thereby augmenting the production of M1‐associated markers, including CCL2, and promoting CCR2‐dependent recruitment of CTLs to the TME, ultimately impeding tumor initiation [126]. The gene discussed is KLF4; the disease is neoplasm.